L
Long Wang
Researcher at GlaxoSmithKline
Publications - 4
Citations - 92
Long Wang is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Reactogenicity & Vaccination. The author has an hindex of 4, co-authored 4 publications receiving 89 citations.
Papers
More filters
Journal ArticleDOI
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
Joanne M. Langley,Long Wang,Naresh Aggarwal,Agustin Bueso,Vijayalakshmi Chandrasekaran,Luis Cousin,Scott A. Halperin,Ping Li,Aixue Liu,Shelly A. McNeil,Lourdes Peña Mendez,Luis Rivera,Bruce L. Innis,Varsha K. Jain +13 more
TL;DR: In children aged 6 to 35 months, a QIV has superior immunogenicity for the added B strain and acceptable immunogenicicity for shared strains, with no notable difference in reactogenicity and safety when compared to a TIV.
Journal ArticleDOI
Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial
Long Wang,Vijayalakshmi Chandrasekaran,Joseph B. Domachowske,Ping Li,Bruce L. Innis,Varsha K. Jain +5 more
TL;DR: The authors compared inactivated seasonal quadrivalent influenza vaccines (QIV) versus TIV (15 and 7.5 μg hemagglutinin [HA] for each influenza strain, respectively) in a phase II randomized (1 : 1), observer-blind trial in US children 6-35 months of age (identifier NCT01974895).
Journal ArticleDOI
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
Varsha K. Jain,Joseph B. Domachowske,Long Wang,Opokua Ofori-Anyinam,Miguel Angel Rodríguez-Weber,Michael Leonardi,Nicola P. Klein,Gary Schlichter,Robert Jeanfreau,Byron L. Haney,Laurence Chu,Jo Ann S. Harris,Kwabena O. Sarpong,Amanda C. Micucio,Jyoti Soni,Vijayalakshmi Chandrasekaran,Ping Li,Bruce L. Innis +17 more
TL;DR: Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.
Journal ArticleDOI
A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine
TL;DR: The thimerosal-containing QIV formulated using a new process was immunogenic, conforming to regulatory acceptance criteria, with a reactogenicity and safety profile in line with the TIV manufactured using a licensed process, which support acceptability of a manufacturing process change in which the thimerosa preservative is added at the point at which batches are filled into multidose vials.